Cargando…
Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway
BACKGROUND: Apigenin is known to have a broad-spectrum efficacy in oxidative stress and conditions due to inflammation, although weak absorption, fast metabolic rate and a fast elimination (systemic) limit the pharmacological efficacy of this drug. Hence, we propose the usage of highly bioavailable...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683501/ https://www.ncbi.nlm.nih.gov/pubmed/33244230 http://dx.doi.org/10.2147/IJN.S256494 |
_version_ | 1783612891871576064 |
---|---|
author | Li, Pingping Bukhari, Syed Nasir Abbas Khan, Tahseen Chitti, Renukaradhya Bevoor, Davan B Hiremath, Anand R SreeHarsha, Nagaraja Singh, Yogendra Gubbiyappa, Kumar Shiva |
author_facet | Li, Pingping Bukhari, Syed Nasir Abbas Khan, Tahseen Chitti, Renukaradhya Bevoor, Davan B Hiremath, Anand R SreeHarsha, Nagaraja Singh, Yogendra Gubbiyappa, Kumar Shiva |
author_sort | Li, Pingping |
collection | PubMed |
description | BACKGROUND: Apigenin is known to have a broad-spectrum efficacy in oxidative stress and conditions due to inflammation, although weak absorption, fast metabolic rate and a fast elimination (systemic) limit the pharmacological efficacy of this drug. Hence, we propose the usage of highly bioavailable Apigenin-solid lipid nanoparticles (SLNPs) to recognize such limitations. The defensive function of Apigenin-SLNPs on renal damage induced by streptozotocin (STZ) in animals was studied. MATERIALS AND METHODS: We initially injected the rats with 35 mg kg(−1) streptozocin intraperitoneally, and after 7 days, the rats were then injected 150 mg kg(−1) of metformin intragastrically followed by a once-daily intragastric dose of Apigenin-SLNP (25 or 50 mg kg(−1)) for a continuous period of 30 days. We then measured the level of insulin and blood glucose, superoxide dismutase, catalase and malondialdehyde in the tissues of the kidney. We also observed messenger-RNA expression of Interleukin-1β, Interleukin-6 and Tumor Necrosis Factor-alpha in renal tissue through RT-PCR technique. Moreover, H&E staining and Western blotting observed the histopathological variations and protein expression of nuclear factor erythroid 2-related factor 2/heme oxygenase/Nuclear Factor-κB signaling pathway, respectively. RESULTS: An enhancement in the expressing of nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 and a suppression in the expression of Nuclear Factor-κB occurred due to Apigenin-SLNPs treatment, which was a result of the protective mechanism of Apigenin-SLNPs which is because of not only its anti-inflammatory function (by inhibition of release of inflammatory factors) but also their anti-oxidant activity (through reduction of lipid peroxidation production). CONCLUSION: We found that a protective effect on diabetic nephropathy was shown due to Apigenin-SLNPs, in rats induced with streptozocin maybe through the pathway of nuclear factor erythroid 2-related factor 2/heme oxygenase-1/Nuclear Factor-κB. |
format | Online Article Text |
id | pubmed-7683501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76835012020-11-25 Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway Li, Pingping Bukhari, Syed Nasir Abbas Khan, Tahseen Chitti, Renukaradhya Bevoor, Davan B Hiremath, Anand R SreeHarsha, Nagaraja Singh, Yogendra Gubbiyappa, Kumar Shiva Int J Nanomedicine Original Research BACKGROUND: Apigenin is known to have a broad-spectrum efficacy in oxidative stress and conditions due to inflammation, although weak absorption, fast metabolic rate and a fast elimination (systemic) limit the pharmacological efficacy of this drug. Hence, we propose the usage of highly bioavailable Apigenin-solid lipid nanoparticles (SLNPs) to recognize such limitations. The defensive function of Apigenin-SLNPs on renal damage induced by streptozotocin (STZ) in animals was studied. MATERIALS AND METHODS: We initially injected the rats with 35 mg kg(−1) streptozocin intraperitoneally, and after 7 days, the rats were then injected 150 mg kg(−1) of metformin intragastrically followed by a once-daily intragastric dose of Apigenin-SLNP (25 or 50 mg kg(−1)) for a continuous period of 30 days. We then measured the level of insulin and blood glucose, superoxide dismutase, catalase and malondialdehyde in the tissues of the kidney. We also observed messenger-RNA expression of Interleukin-1β, Interleukin-6 and Tumor Necrosis Factor-alpha in renal tissue through RT-PCR technique. Moreover, H&E staining and Western blotting observed the histopathological variations and protein expression of nuclear factor erythroid 2-related factor 2/heme oxygenase/Nuclear Factor-κB signaling pathway, respectively. RESULTS: An enhancement in the expressing of nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 and a suppression in the expression of Nuclear Factor-κB occurred due to Apigenin-SLNPs treatment, which was a result of the protective mechanism of Apigenin-SLNPs which is because of not only its anti-inflammatory function (by inhibition of release of inflammatory factors) but also their anti-oxidant activity (through reduction of lipid peroxidation production). CONCLUSION: We found that a protective effect on diabetic nephropathy was shown due to Apigenin-SLNPs, in rats induced with streptozocin maybe through the pathway of nuclear factor erythroid 2-related factor 2/heme oxygenase-1/Nuclear Factor-κB. Dove 2020-11-19 /pmc/articles/PMC7683501/ /pubmed/33244230 http://dx.doi.org/10.2147/IJN.S256494 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Pingping Bukhari, Syed Nasir Abbas Khan, Tahseen Chitti, Renukaradhya Bevoor, Davan B Hiremath, Anand R SreeHarsha, Nagaraja Singh, Yogendra Gubbiyappa, Kumar Shiva Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title | Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title_full | Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title_fullStr | Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title_full_unstemmed | Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title_short | Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway |
title_sort | apigenin-loaded solid lipid nanoparticle attenuates diabetic nephropathy induced by streptozotocin nicotinamide through nrf2/ho-1/nf-kb signalling pathway |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683501/ https://www.ncbi.nlm.nih.gov/pubmed/33244230 http://dx.doi.org/10.2147/IJN.S256494 |
work_keys_str_mv | AT lipingping apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT bukharisyednasirabbas apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT khantahseen apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT chittirenukaradhya apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT bevoordavanb apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT hiremathanandr apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT sreeharshanagaraja apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT singhyogendra apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway AT gubbiyappakumarshiva apigeninloadedsolidlipidnanoparticleattenuatesdiabeticnephropathyinducedbystreptozotocinnicotinamidethroughnrf2ho1nfkbsignallingpathway |